ArticleClinical journal of oncology nursing2025
Examining the Use of Serum Biomarkers to Guide Early Detection of Pancreatic Cancer.
Article in Clinical journal of oncology nursing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer is estimated to become the second leading cause of cancer-related death by 2030 because of high malignancy, late diagnosis, inefficient therapy, and a lack of available screening for early detection.
objectivesThis article presents current clinical data supporting the use of serum biomarker signatures as a modality for early pancreatic ductal adenocarcinoma (PDAC) diagnosis and treatment.
methodsA clinical case study highlights the use of serum biomarker signatures in PDAC diagnosis. Clinical guidelines on PDAC were obtained from the National Comprehensive Cancer Network, the National Cancer Institute, StatPearls Publishing, the American Cancer Society, and the Pancreatic Cancer Detection Consortium.
findingsScreening barriers involve a low incidence and histologic heterogeneity of disease, as well as a need for prospective multicenter analysis of proposed biomarkers. Because the poor prognosis of PDAC is attributed to late detection, the development of a clinical guideline for biomarker-based screening warrants interprofessional awareness and advocacy in oncology clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.